Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment

• US 7,141,548 B2
• Filed: 06/04/2004
• Issued: 11/28/2006
• Est. Priority Date: 04/09/2003
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk Health Care AG (Novo Nordisk A/S)
• Original Assignee: Novo Nordisk A/S
• Inventors: Johansen, Thue, Malmlof, Kjell
• Primary Examiner(s): O'Hara, Eileen B.
• Assistant Examiner(s): Chandra, Gyan
• Application Number:
  US10/861,004
• Publication Number:
  US 20040220109A1
• Time in Patent Office: 907 Days
• Field of Search: 514/12, 514/866, 514/909, 436/71, 424/9.1
• US Class Current: 514/5.3
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 38/553 Renin inhibitors

Abstract

The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.

Claims

1. A method for reducing the incidence of a statistically significant rise in plasma insulin levels in an animal or human subject undergoing treatment with growth hormone (GH), comprising providing the subject, during the growth hormone treatment period, with a restricted amount of a high-fat (HF) diet as the sole food source.

2. The method of claim 1, wherein the energy content of the diet does not exceed the theoretical maintenance level for the subject.

3. The method of claim 2, wherein the subject is a human.

4. The method of claim 3, wherein the human is obese.

5. The method of claim 1, wherein the subject is a human.

6. The method of claim 5, wherein the human is obese.